http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 23 Jun 2026 05:43:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/TD+Cowen+Starts+Nkarta+Inc.+%28NKTX%29+at+Buy/26675119.html (Updated - June 23, 2026 5:43 AM EDT) <p>TD Cowen analyst Phil Nadeau initiates coverage on Nkarta Inc. (NASDAQ: NKTX) with a Buy rating.</p><p>The analyst commented: "Nkarta is focused on the development of engineered natural killer (NK) cell therapies. Lead candidate NKX019 is a CD19 CAR NK in 2 Ph. I trials in a range of autoimmune diseases where it has the potential to meaningfully advance the standard of care. Initial data are anticipated in 2026. We expect NKTX to create much long-term shareholder value as NKX019 advances through clinical development."</p><p>For an analyst ratings summary and ratings history on Nkarta Inc. http://www.streetinsider.com/New+Coverage/TD+Cowen+Starts+Nkarta+Inc.+%28NKTX%29+at+Buy/26675119.html Tue, 23 Jun 2026 05:43:37 -0400 NKTX http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Starts+Nkarta+Inc.+%28NKTX%29+at+Buy/26675119.html (Updated - June 23, 2026 5:43 AM EDT) <p>TD Cowen analyst Phil Nadeau initiates coverage on Nkarta Inc. (NASDAQ: NKTX) with a Buy rating.</p><p>The analyst commented: "Nkarta is focused on the development of engineered natural killer (NK) cell therapies. Lead candidate NKX019 is a CD19 CAR NK in 2 Ph. I trials in a range of autoimmune diseases where it has the potential to meaningfully advance the standard of care. Initial data are anticipated in 2026. We expect NKTX to create much long-term shareholder value as NKX019 advances through clinical development."</p><p>For an analyst ratings summary and ratings history on Nkarta Inc. http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Starts+Nkarta+Inc.+%28NKTX%29+at+Buy/26675119.html Tue, 23 Jun 2026 05:43:37 -0400 NKTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+18++Filed+by%3A+HASTINGS+PAUL+J/26672981.html si-local-file:///var/storage/secattach/20260622/26672981.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+18++Filed+by%3A+HASTINGS+PAUL+J/26672981.html Mon, 22 Jun 2026 16:05:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+18++Filed+by%3A+HASTINGS+PAUL+J/26672981.html si-local-file:///var/storage/secattach/20260622/26672981.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+18++Filed+by%3A+HASTINGS+PAUL+J/26672981.html Mon, 22 Jun 2026 16:05:00 -0400 NKTX O.38360402 http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10/26636587.html si-local-file:///var/storage/secattach/20260611/26636587.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10/26636587.html Thu, 11 Jun 2026 16:59:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10/26636587.html si-local-file:///var/storage/secattach/20260611/26636587.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10/26636587.html Thu, 11 Jun 2026 16:59:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Shah+Rajeev+M./26636200.html si-local-file:///var/storage/secattach/20260611/26636200.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Shah+Rajeev+M./26636200.html Thu, 11 Jun 2026 16:31:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Shah+Rajeev+M./26636200.html si-local-file:///var/storage/secattach/20260611/26636200.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Shah+Rajeev+M./26636200.html Thu, 11 Jun 2026 16:31:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Behbahani+Ali/26636082.html si-local-file:///var/storage/secattach/20260611/26636082.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Behbahani+Ali/26636082.html Thu, 11 Jun 2026 16:27:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Behbahani+Ali/26636082.html si-local-file:///var/storage/secattach/20260611/26636082.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Behbahani+Ali/26636082.html Thu, 11 Jun 2026 16:27:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+George+Simeon/26635989.html si-local-file:///var/storage/secattach/20260611/26635989.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+George+Simeon/26635989.html Thu, 11 Jun 2026 16:21:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+George+Simeon/26635989.html si-local-file:///var/storage/secattach/20260611/26635989.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+George+Simeon/26635989.html Thu, 11 Jun 2026 16:21:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Vratsanos+George/26635754.html si-local-file:///var/storage/secattach/20260611/26635754.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Vratsanos+George/26635754.html Thu, 11 Jun 2026 16:11:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Vratsanos+George/26635754.html si-local-file:///var/storage/secattach/20260611/26635754.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+Vratsanos+George/26635754.html Thu, 11 Jun 2026 16:11:00 -0400 NKTX O.38360402 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+PATTERSON+LEONE+D/26635687.html si-local-file:///var/storage/secattach/20260611/26635687.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Nkarta%2C+Inc.++++++++++++++For%3A+Jun+10++Filed+by%3A+PATTERSON+LEONE+D/26635687.html Thu, 11 Jun 2026 16:08:00 -0400 NKTX O.38360402